Prazosin in the treatment of hypertension.
In two double-blind, randomized cross-over comparison studies undertaken in elderly subjects, a new quinazoline derivative, prazosin, has been shown to be a safe and effective antihypertensive agent to which there is a progressive response over four- to six-week periods of oral administration at fixed dose-levels.
D000284:Administration, Oral; D000368:Aged; D000959:Antihypertensive Agents / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D008297:Male; D008750:Methyldopa / Q000627:therapeutic use; D008875:Middle Aged; D010879:Piperazines / Q000627:therapeutic use*; D010919:Placebos; D011187:Posture; D011799:Quinazolines / Q000627:therapeutic use*
D000959:Antihypertensive Agents; D010879:Piperazines; D010919:Placebos; D011799:Quinazolines; D008750:Methyldopa